Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lurbinectedin and Irinotecan in Advanced DSRCT
NCT07328425Phase 2Recruiting
- Sponsor
- Italian Sarcoma Group
- Start
- Nov 2025
- Primary completion
- Oct 2030
- Modality
- Classical Binding Small Molecules, DNA Intercalators/Alkylators
- Countries
- 2
01
Overview
A Phase 2 trial of lurbinectedin in desmoplastic small round cell tumor (DSRCT), sponsored by Italian Sarcoma Group. Started Nov 2025; status: recruiting.
02
Drugs
lurbinectedin
03
Conditions
desmoplastic small round cell tumor (DSRCT)
Beyond the preview
Go deeper on NCT07328425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07328425.